Pediatrix Medical Group (MD) Q3 Earnings Report Preview: What To Look For

Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting results this Monday before market hours. Here’s what to look for.

Pediatrix Medical Group beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $468.8 million, down 7% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ same-store sales estimates and a beat of analysts’ EPS estimates.

Is Pediatrix Medical Group a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Pediatrix Medical Group’s revenue to decline 6.5% year on year to $477.7 million, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.47 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Pediatrix Medical Group has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Pediatrix Medical Group’s peers in the healthcare providers & services segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Guardant Health delivered year-on-year revenue growth of 38.5%, beating analysts’ expectations by 12.6%, and CVS Health reported revenues up 7.8%, topping estimates by 4.1%. Guardant Health traded up 27.9% following the results while CVS Health was down 6.7%.

Read our full analysis of Guardant Health’s results here and CVS Health’s results here.

Investors in the healthcare providers & services segment have had steady hands going into earnings, with share prices flat over the last month. Pediatrix Medical Group is down 3% during the same time and is heading into earnings with an average analyst price target of $16.75 (compared to the current share price of $16.97).

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.